Inxight Drugs

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Return Home Inxight Drugs

Home
Browse Drugs
Search
- Structure Search
- Sequence Search
Downloads
About

Show Filters

Hide Filters

Development Status

US Approved Rx

2

Other

1

All Match

Any Match

Exclude Selected

Exclude Selected

Primary Target

Voltage-gated potassium channel subunit Kv1.3

2

All Match

Any Match

Exclude Selected

Exclude Selected

Highest Phase

Approved

2

All Match

Any Match

Exclude Selected

Exclude Selected

Approval Year

2010

2

Unknown

1

All Match

Any Match

Exclude Selected

Exclude Selected

Condition

Multiple sclerosis

2

All Match

Any Match

Exclude Selected

Exclude Selected

Treatment Modality

Primary

2

All Match

Any Match

Exclude Selected

Exclude Selected

CNS Activity

CNS Active

2

All Match

Any Match

Exclude Selected

Exclude Selected

Originator

Chichibabin, A.E.

2

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Class

Chemical

3

All Match

Any Match

Exclude Selected

Exclude Selected

Code System

CAS

3

EPA CompTox

3

FDA UNII

3

NSC

3

PUBCHEM

3

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 1

NERVOUS SYSTEM

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 2

OTHER NERVOUS SYSTEM DRUGS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 3

OTHER NERVOUS SYSTEM DRUGS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 4

Other nervous system drugs

1

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Form

Principal Form

2

Salts, Hydrates, Esters, etc.

1

All Match

Any Match

Exclude Selected

Exclude Selected

Showing 1 - 3 of 3 results

First page disabled
Previous page disabled
1
Next page disabled
Next page disabled

4-Aminopyridine hydrochloride

897AWS9WZQ

Export Data
Search for Structure

Status:

US Approved Rx (2018)

First approved in 2010

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Voltage-gated potassium channel subunit Kv1.3

Conditions:

Multiple sclerosis

Dalfampridine is a potassium channel blocker, used as a research tool in characterizing subtypes of the potassium channel. Dalfampridine has also been used as a drug, to manage some of the symptoms of multiple sclerosis, and is indicated for symptoma...

tic improvement of walking in adults with several variations of the disease. The mechanism by which dalfampridine exerts its therapeutic effect has not been fully elucidated. Dalfampridine is a broad spectrum potassium channel blocker. In animal studies, dalfampridine has been shown to increase conduction of action potentials in demyelinated axons through inhibition of potassium channels.

2-BROMOPYRIDINE

7Z7MLC4VD8

Export Data
Search for Structure

Status:

Other

Class (Stereo):

CHEMICAL (ACHIRAL)

DALFAMPRIDINE

BH3B64OKL9

Export Data
Search for Structure

Status:

US Approved Rx (2018)

First approved in 2010

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Voltage-gated potassium channel subunit Kv1.3

Conditions:

Multiple sclerosis

Dalfampridine is a potassium channel blocker, used as a research tool in characterizing subtypes of the potassium channel. Dalfampridine has also been used as a drug, to manage some of the symptoms of multiple sclerosis, and is indicated for symptoma...

tic improvement of walking in adults with several variations of the disease. The mechanism by which dalfampridine exerts its therapeutic effect has not been fully elucidated. Dalfampridine is a broad spectrum potassium channel blocker. In animal studies, dalfampridine has been shown to increase conduction of action potentials in demyelinated axons through inhibition of potassium channels.

HHS VULNERABILITY DISCLOSURE

For language access assistance, contact the NCATS Public Information Officer

National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966


			version 1.1